Mineralys Therapeutics, Inc. MLYS Capitalized research and development costs
Capitalized research and development costs at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept mlys:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s capitalized research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s capitalized research and development costs?
- Mineralys Therapeutics, Inc. (MLYS) reported capitalized research and development costs of $39.94M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s capitalized research and development costs?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s capitalized research and development costs has grown at a 95.2% compound annual growth rate (CAGR), from $5.37M to $39.94M.
- What does capitalized research and development costs mean?
- This metric captures research and development expenditures that have been recorded as an asset on the balance sheet rather than being expensed immediately in the period incurred. It reflects the company's accounting treatment of development costs that are expected to provide future economic benefits, often related to specific regulatory or tax requirements. Tracking this helps investors understand the company's capitalization policy and the underlying investment in its product pipeline.